Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MRE (medco research) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (102)	7/4/1998 4:25:00 PM
From: Xiaoping Zhang	Read Replies (3) \| Respond to of 192

Re: Pipeline of drugs. Scott: I am new to this stock and have limited information on the pipeline. I hope others can join the discussion. The following is what I know about the question: (1) IBD had a nice write-up about MRE on 6/12/98. I type the relevant information below: Adenocard - Approved. Adenoscan - Approved. Intravenous adenosine for cardiology - Clinical phase II (almost no doubt, this is MEDR640). A2a agonists, A1 antagonists - Preclinical. Allosteric modulators - Preclinical. (2) You can request a copy of "A symposium: cardiovascular effects of adenosin from receptors to bedside". From there you will get clues for a Medline search if you are inclined to do so. I requested the copy and might do a Medline search if I am interested in this enough. (3) I read somewhere on the Net that the company has bought a library of compounds (the 100 or so A2a receptor-selected agonists mentioned in the IBD article?). This tells me that the company is very serious about R&D of these potential drugs in the pipeline. IMHO, it is really too far down the road for us to concern about most drug candidates in the pipeline at their early stages. For every 20 or so R&D projects, only one finally brings a drug to the market. But MEDR640 is a different story; unlike many highly touted candidates in the investment universe, such as ENMD's Angiostatin and Endostatin, MEDR640 has a real chance (more than 50%?) to succeed. If in two years MEDR640 goes to the market, we win; if it fails, the stock price plummets. X.Z. 7/4